Abstract: The invention relates to a method for subjecting adherent cells to at least one electric field, in which the electric field is generated by applying a voltage to at least two active electrodes 63, wherein at least three electrodes 63, 64 are provided, and wherein at least two electrodes 63, 64 are active electrodes 63 when the voltage is applied in order to generate a first electric field, and in which at least one second electric field is generated, wherein at least one of the two previously active electrodes 63 is a potential-free electrode 64 when the voltage is applied.
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
July 11, 2017
Assignee:
LONZA COLOGNE GMBH
Inventors:
Thomas Koblizek, Andreas Heinze, Timo Gleissner, Herbert Mueller-Hartmann, Andreas Wirth
Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
Type:
Grant
Filed:
March 10, 2013
Date of Patent:
April 4, 2017
Assignee:
International AIDS Vaccine Initiative
Inventors:
Svetlana Rabinovich, Maoli Yuan, Aaron J. Wilson, Sanjay Phogat, Ross W. B. Lindsay, Maria J. Chiuchiolo, Christopher L. Parks
Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
Type:
Grant
Filed:
February 22, 2006
Date of Patent:
October 25, 2016
Assignee:
The United States of America, as represented by the Secretary of the Department of Health and Human Services
Inventors:
Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
Abstract: Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor.
Type:
Grant
Filed:
November 13, 2013
Date of Patent:
August 11, 2015
Assignee:
Celgene Corporation
Inventors:
Aaron N. Nguyen, Kyle J. MacBeth, Jorge DiMartino
Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
Type:
Grant
Filed:
November 20, 2013
Date of Patent:
July 14, 2015
Assignee:
TRIPEP AB
Inventors:
Matti Sällberg, Anders Vahlne, Maria Perdomo
Abstract: A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396th position and the 410th position from the C-terminal of DP-1.
Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
July 14, 2015
Assignee:
The Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Abstract: The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (?AKTLLPTPGGS(PEG5000))4 KKKKDOTA?A-NH2, to which imaging agents and/or therapeutic agents can be conjugated.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
July 7, 2015
Assignee:
University of Virginia Patent Foundation
Abstract: A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly)5, Pro-Hyp, Hyp-Gly, Pro-Gly, Pro-Pro and Ala-Hyp or a chemically-modified substance thereof or a pharmaceutically acceptable salt thereof have DPPTV inhibitory activity and/or GLP-1 secretion accelerating activity, and hence are effective as a therapeutic or preventive agent or the like for diabetes.
Abstract: The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of inter alia conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilized are represented by the general formula (I), as further defined in the specification.
Abstract: Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.
Type:
Grant
Filed:
April 6, 2012
Date of Patent:
June 2, 2015
Assignee:
IMMUNE DESIGN CORP.
Inventors:
Thomas W. Dubensky, Jr., Scott H. Robbins
Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.
Abstract: Methods and apparatus are disclosed for determining the occurrence of a closed or open apnea. Respiratory air flow from a patient is measured to give an air flow signal. The determination of an apnea is performed by applying an oscillatory pressure waveform of known frequency to a patient's airway, calculating a complex quantity representing a patient admittance (12) and comparing its value with ranges (14,16) indicative of open or closed apneas. The method distinguishes open from closed apneas even when the model used to calculate admittance is not based on details of the respiratory apparatus. In addition the patient admittance may be compared with admittance during normal breathing to avoid having to characterize the airway.
Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, the recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against the RNA virus or against both measles virus and against the RNA virus. It also relates to the use of the recombinant measles virus for the preparation of immunogenic compositions.
Type:
Grant
Filed:
February 4, 2010
Date of Patent:
April 21, 2015
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
Type:
Grant
Filed:
July 24, 2008
Date of Patent:
April 14, 2015
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Frédéric Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
Abstract: A simple and convenient method for concentrating a biomolecule, including protein or nucleic acid molecules, from a sample. Purified and isolated biomolecules obtained by this method. Methods for improving the specificity or sensitivity of detecting a biomolecule by concentration and/or purification or isolation of the biomolecule according to the method of the invention.
Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain, for example, the Schwarz strain. It also concerns the preparation of infectious recombinant viruses and immunogenic compositions using the cDNA.
Type:
Grant
Filed:
December 17, 2004
Date of Patent:
April 14, 2015
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Fréderic Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
Type:
Grant
Filed:
April 8, 2010
Date of Patent:
April 14, 2015
Assignee:
Crucell Holland B.V.
Inventors:
Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
Type:
Grant
Filed:
August 13, 2010
Date of Patent:
April 7, 2015
Assignee:
Genexine, Inc.
Inventors:
Young Chul Sung, Sang Hwan Seo, You Suk Suh
Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.
Type:
Grant
Filed:
April 2, 2013
Date of Patent:
April 7, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services